遗传学家陆元成开发的衰老逆转技术取得临床突破。1Life Biosciences公司于2024年6月9日宣布，将该技术衍生的药物ER-100注射到一名青光眼患者眼中，标志着这项技术首次进入人体临床试验。1
该技术基于OSK基因疗法，由OSKM四基因中去除致癌风险基因Myc后的版本组成。1陆元成曾在2018年哈佛医学院博士期间利用这一技术成功修复了小鼠的损伤视神经并恢复其视力，相关研究成果于2020年发表在《Nature》杂志上。1今年，陆元成进一步识别出一个负责保护视网膜免受自由基伤害的基因，这是与年龄相关的黄斑变性的主要原因。1实验室负责人David Sinclair同时担任Life Biosciences的联合创始人。1
Geneticist Lu Yuancheng has developed an age-reversal technique using OSK gene therapy to repair age-related damage, which successfully restored vision in mice with damaged optic nerves during experiments conducted in 2018 while he was pursuing his doctorate at Harvard Medical School1. The therapy is based on a modified version of the OSKM four-gene framework, with the cancer-risk gene Myc removed to enhance safety1. Lu's groundbreaking research was published in Nature in 20201.
The technology has now advanced to human clinical application. On June 9, 2024, Life Biosciences announced that it had injected ER-100, a drug derived from this age-reversal approach, directly into the eye of a glaucoma patient, marking the transition from basic research to clinical trials1. This year, Lu identified a gene responsible for protecting the retina from free radical damage, which is a primary cause of age-related macular degeneration1. David Sinclair, the laboratory director and co-founder of Life Biosciences, leads the research effort1.
评论
还没有评论，欢迎留下第一条。